Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …
EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European heart …, 2014 - academic.oup.com
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies
Background: Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein
convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol …
convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol …
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long …
MJ Koren, RP Giugliano, FJ Raal, D Sullivan… - Circulation, 2014 - Am Heart Assoc
Background—Evolocumab (AMG 145), a monoclonal antibody against proprotein
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
[HTML][HTML] A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American journal of …, 2016 - Elsevier
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott… - … England Journal of …, 2015 - Mass Medical Soc
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk–Primary …
A Hirayama, N Honarpour, M Yoshida… - Circulation …, 2014 - jstage.jst.go.jp
Background: YUKAWA is a 12-week, randomized, double-blind, placebocontrolled, phase 2
study evaluating the efficacy and safety of evolocumab (AMG 145) in statin-treated …
study evaluating the efficacy and safety of evolocumab (AMG 145) in statin-treated …
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Purpose Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we
investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. Methods …
investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. Methods …
Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials
ND Wong, MD Shapiro - Frontiers in Cardiovascular Medicine, 2019 - frontiersin.org
The recent development of monoclonal antibodies targeted to proprotein convertase
subtilisin/kexin type 9 (PCSK9), eg, PCSK9 inhibitors has revolutionized the landscape of …
subtilisin/kexin type 9 (PCSK9), eg, PCSK9 inhibitors has revolutionized the landscape of …
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
MJ Koren, P Lundqvist, M Bolognese, JM Neutel… - Journal of the American …, 2014 - jacc.org
Objectives: The aim of this study was to compare biweekly and monthly evolocumab with
placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial …
placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial …
相关搜索
- efficacy and safety evolocumab in patients
- pcsk9 inhibitor evolocumab in patients
- monoclonal antibody effects of evolocumab
- monoclonal antibody japanese patients
- efficacy and safety pcsk9 inhibitor
- cardiovascular events safety of evolocumab
- mixed hyperlipidemia evolocumab in patients
- japanese patients effects of evolocumab
- safety analysis open label
- efficacy and safety mixed hyperlipidemia
- patients with hypercholesterolemia safety of evolocumab
- efficacy and safety cardiovascular events